Nagasawa Michiaki, Hara Tomoko, Kashino Ai, Akasaka Yunike, Ide Tomohiro, Murakami Koji
Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., 2399-1 Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
Biochem Pharmacol. 2009 Sep 1;78(5):523-30. doi: 10.1016/j.bcp.2009.05.007. Epub 2009 May 9.
Peroxisome proliferator-activated receptor-alpha (PPARalpha) is a key regulator in hepatic lipid metabolism and is a potential therapeutic target for dyslipidaemia. We reported previously that human hepatic apoA-IV is a highly sensitive gene up-regulated by the PPARalpha agonist KRP-101 (KRP), suggesting that induction of apoA-IV expression is one of the mechanisms underlying the decrease in triglycerides and elevation of HDL observed with PPARalpha agonist treatment. However, the mechanism of transcriptional regulation of apoA-IV by PPARalpha activation remains unclear. To clarify whether the apoA-IV promoter is regulated directly by PPARalpha, we analysed the apoA-IV promoter region by transient transfection assay in the human hepatocellular carcinoma cell line, HepG2. Co-transfection assay of unilateral deletions of apoA-IV promoter construct with human PPARalpha/RXRalpha showed that the region from -3279 to -2261 of the apoA-IV promoter includes key sites for transactivation by PPARalpha/RXRalpha. Sequence analysis suggested three putative PPAR response elements (PPREs) in this region. Electrophoretic mobility shift assay (EMSA) showed that a PPRE located from -2979 to -2967 can bind to PPARalpha/RXRalpha. Moreover, site-directed mutagenesis experiments indicated that the -2979/-2967 PPRE plays an essential role in transcriptional regulation of apoA-IV by PPARalpha. Chromatin immunoprecipitation (ChIP) assay confirmed that ligand-induced binding of PPARalpha to endogenous -2979/-2967 PPRE. These results indicate that human apoA-IV is regulated directly by PPARalphavia the -2979/-2967 PPRE.
过氧化物酶体增殖物激活受体α(PPARα)是肝脏脂质代谢的关键调节因子,也是血脂异常的潜在治疗靶点。我们之前报道过,人肝脏载脂蛋白A-IV(apoA-IV)是一种对PPARα激动剂KRP-101(KRP)高度敏感的上调基因,这表明apoA-IV表达的诱导是PPARα激动剂治疗导致甘油三酯降低和高密度脂蛋白升高的潜在机制之一。然而,PPARα激活对apoA-IV转录调控的机制仍不清楚。为了阐明apoA-IV启动子是否直接受PPARα调控,我们在人肝癌细胞系HepG2中通过瞬时转染实验分析了apoA-IV启动子区域。将apoA-IV启动子构建体的单侧缺失与人类PPARα/RXRα进行共转染实验表明,apoA-IV启动子从-3279到-2261的区域包含PPARα/RXRα反式激活的关键位点。序列分析表明该区域存在三个假定的PPAR反应元件(PPREs)。电泳迁移率变动分析(EMSA)显示位于-2979至-2967的一个PPRE可与PPARα/RXRα结合。此外,定点诱变实验表明-2979/-2967 PPRE在PPARα对apoA-IV的转录调控中起关键作用。染色质免疫沉淀(ChIP)实验证实配体诱导PPARα与内源性-2979/-2967 PPRE结合。这些结果表明人apoA-IV通过-2979/-2967 PPRE直接受PPARα调控。